medigraphic.com
ISSN 2594-1526 (Digital)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2008, Número 1

<< Anterior

Neumol Cir Torax 2008; 67 (1)


Consideraciones a los resultados de tratamiento en pacientes con tuberculosis resistente a múltiples fármacos (TB MDR). Una revisión de la literatura

Martínez MD, López SE, Torres CA, Ruiz PV, Mora PMÁ, Salazar LMÁ

Idioma: Español
Referencias bibliográficas: 33
Paginas: 34-43
Archivo PDF: 137.61 Kb.


RESUMEN

La tuberculosis multifarmacorresistente (MDR), definida como aquélla en que la cepa es resistente al menos a isoniazida y rifampicina, es el resultado de un mal manejo en el pasado, y un fenómeno creado por el hombre. Existen evidencias y controversias en el tratamiento y curación de los pacientes con TB MDR. Los trabajos revisados en este estudio demuestran tasas de curación que van del 33 al 77%, las definiciones de curación varían entre los trabajos publicados. Aunque la factibilidad y costo-efectividad de tratar pacientes con TB MDR en países de medianos-bajos recursos está bien establecido, el éxito de tratamiento permanece subóptimo, principalmente debido a la duración del mismo y a los efectos adversos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Guidelines for the programatic management of drug-resistant tuberculosis. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.361).

  2. Nettleman MD. Multidrug-Resistant Tuberculosis News from the front. JAMA 2005; 293(22): 2788-2790.

  3. Salazar-Lezama MA. Tratamiento de la tuberculosis farmacorresistente. Gac Méd Méx 2003; 139(5): 487-490.

  4. Burgos M, González LC, Paz EA, Gournis E, Kawamura LM, Schecter G, Hopewell PC, Daley CL. Treatment of multidrug-resistant tuberculosis in San Francisco: An outpatient-based approach. CID 2005: 40 (1 April).

  5. Ollé-Goig JE, Sandy R. Outcomes of individualized treatment for multidrug-resistant tuberculosis before DOTS-Plus. Int J Tuberc Lung Dis 2005; 9(7): 765-770.

  6. Flement-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.

  7. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9(5): 507-513.

  8. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.

  9. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at chest clinic. Int J Tuberc Lung Dis 2001; 5(12): 1129-1136.

  10. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 Patients with Pulmonary Tuberulosis Resistant to Isoniazid and Rifampin. N Engl J Med 1993; 328: 527-532.

  11. Salazar-Lezama MA, Torres-Cruz A, Valdez-Vázquez R, López-Segundo E, Villarreal-Velarde H, Quiñones Falconi F, et al. Resultados de tratamiento de tuberculosis resistente en 91 pacientes del Instituto Nacional de Enfermedades Respiratorias: 2001-2003. Rev Inst Nal Enf Resp Mex 2004; 17(1): 15-21.

  12. Pérez-Guzmán C, Vargas MH, Martínez-Rossier LA, Torres-Cruz A, Villarreal-Velarde H. Result of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 6(12): 1-8.

  13. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8(3): 361-368.

  14. Tahao lu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Özmen I, Kapakli N. The Trealment of Multidrug-resistant Tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.

  15. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh MN, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.

  16. Ward HA, Marciniuk DD, Hoeppner VH, Jones W. Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants. Int J Tuberc Lung Dis 2005; 9(2): 164-169.

  17. Escudero E, Peña JM, Álvarez-Sala R, Vázquez JJ, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualized therapy. Int J Tuberc Lung Dis 2006; 10(4): 409-414.

  18. Park SK, Tim SD, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2(11): 877-884.

  19. Wai YW, Kuen CC, Hung CC, Ming TC, Chiu LC, Chuen WP, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. CHEST 2000; 117: 744-751.

  20. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Andreev YG, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10(4): 402-409.

  21. Van DA, Hamid SM, Kumar DA, Bastian I, Portales F. Results of a standardized regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8(5): 560-567.

  22. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993 prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.

  23. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment Experience of Multidrug-Resistant Tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-348.

  24. Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, et al. Multidrug-Resistant Tuberculosis in Patients without HIV Infection. N Engl J Med 1995; 333: 907-911.

  25. Holtz TH, Sternberg M, Kammerer S, Laserson K F, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: Predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.

  26. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.

  27. Nathason E, Lambregts C, Rich M, Gupta R, Bayona J, Blönda K, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infec Dis 2006; 12: 1389-1397.

  28. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9(6): 640-645.

  29. Kwonjune JS, Irina EG, Gennadiy GP, Vera TG, Vera EP, Olga BS, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. CID 2004; 39: 1321-1328.

  30. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25: 928-936.

  31. DeRiemer K, García-García L, Bobadilla-del-Valle M, Palacios-Martínez M, Martínez-Gamboa A, Small PM et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245.

  32. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 10(8): 829-837

  33. Mitnick CD, Castro KG, Harrington M, Sacks Burman W. (2007). Randomized trials to optimize treatment of multidrug-resistant tuberculosis. Plos Med 4(11);e292.doi:10.1371/journal.pmed.0040292.




2020     |     www.medigraphic.com